Of the 39 companies we reviewed, 13% are publicly traded and 44% are venture-backed
The platform is positioned for people who are already on a GLP-1 medication - Ozempic, Wegovy, Mounjaro, Zepbound, or similar - and want a structured way to track what happens to their body composition, specifically their lean muscle tissue, while the medication is driving weight loss
Exendin 939 did not affect proton-induced TRPV1 activation, suggesting its selective antagonism
Portions look oversized
It also supports bone health (since bones stay stronger when you do weight-bearing activities)
We provide transparent pricing with no required subscriptions, although costs vary by medication, dose, pharmacy pricing, and available coverage